-
01.09.2025 | CARB-X funds Peptilogics to develop a novel, broad-spectrum therapeutic to treat fracture-related infections
CARB-X will award Peptilogics $3.3 million to develop and execute a workplan for its slow-release formulation of a novel, broad-spectrum therapeutic, zaloganan-CR, an engineered peptide intended for use in preventing infection after high-energy-traumatic bone injuries.
-
01.07.2025 | CARB-X funds Clarametyx Biosciences to develop anti-biofilm vaccine
CARB-X will award Clarametyx Biosciences US$2.6 million to develop a Lead Optimization workplan to support its novel broad-spectrum, anti-biofilm vaccine program.
Toggle navigation